Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-J591
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-J591 is a radioimmunotherapeutic agent consisting of the monoclonal antibody J591 conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Developed at Weill Cornell Medicine (formerly Weill Medical College of Cornell University), it specifically targets the extracellular domain of prostate-specific membrane antigen (PSMA), a protein highly overexpressed on the surface of virtually all prostate cancer cells, particularly in metastatic and treatment-resistant disease. The J591 antibody serves as a delivery vehicle to bring localized radiation directly to cancer cells throughout the body, inducing DNA damage and cell death while minimizing exposure to healthy tissues. This biologic therapy has been evaluated in Phase I and Phase II clinical trials for metastatic castration-resistant prostate cancer (mCRPC), both as a monotherapy and in combination with other PSMA-targeting agents such as 177Lu-PSMA-617.
- Other names
- Lutetium Lu 177 J591177Lu-DOTA-J591177Lu-labeled monoclonal antibody J591
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-J591.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-J591.